Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stake Lowered by Creative Planning

Creative Planning reduced its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 7.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 189,367 shares of the company’s stock after selling 15,815 shares during the period. Creative Planning’s holdings in Lineage Cell Therapeutics were worth $169,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LCTX. Defender Capital LLC. bought a new stake in Lineage Cell Therapeutics in the third quarter worth $3,709,000. State Street Corp bought a new stake in Lineage Cell Therapeutics in the third quarter worth $1,738,000. Rhumbline Advisers bought a new stake in Lineage Cell Therapeutics in the third quarter worth $177,000. California State Teachers Retirement System bought a new stake in Lineage Cell Therapeutics in the third quarter worth $163,000. Finally, Commonwealth Equity Services LLC bought a new stake in Lineage Cell Therapeutics in the third quarter worth $112,000.

LCTX stock opened at $1.51 on Friday. Lineage Cell Therapeutics, Inc. has a 52-week low of $0.53 and a 52-week high of $1.73. The company’s 50-day moving average price is $0.98.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.94 million.

A number of equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, February 10th. Zacks Investment Research cut shares of Lineage Cell Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $2.67.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Read More: What are economic reports?

Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX).

Institutional Ownership by Quarter for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.